FDA Standard Drug Review Goals Could be Lengthened By 1-2 Months, IG Says
This article was originally published in The Tan Sheet
Executive Summary
FDA should consider extending by one or two months its 10-month goal for standard drug reviews, the HHS Inspector General said in a 1report released March 25